Press Release Details

Cerus Corporation to Host Investor and Analyst Event on November 9th in New York City

October, 26 2008

CONCORD, Calif. -- Cerus Corporation (NASDAQ:CERS) announced today that it will host an Investor and Analyst Event on November 9, 2006, in New York City.

The event will feature presentations and comments from company management providing an overview of Cerus' European operations, commercialization progress for the INTERCEPT Blood System for platelets and plasma, a clinical update on the company's immunotherapy programs and an update on research and development efforts. External blood safety and immunotherapy experts will also make presentations during the event. The four-hour event will be held at the Roosevelt Hotel, 45 East 45thStreet, New York, and will be broadcast live over the Internet beginning at 8:30 a.m. Eastern Time.

Investment professionals interested in attending Cerus' November 9th Investor and Analyst Event in New York City should contact Myesha Edwards at (925) 288-6017 or medwards@cerus.com.

To access the webcast, please log on to the Company's website at www.cerus.com at least 15 minutes prior to the start of the meeting to allow adequate time for any software downloads that may be required. A replay of the event will be available through November 16, 2006.

About Cerus

Cerus Corporation is a biopharmaceutical company that develops and commercializes novel, proprietary products in the fields of blood safety and immunotherapy to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of immunotherapy, the company is employing its proprietary attenuated Listeria vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in research and development of prophylactic and therapeutic vaccines for infectious diseases. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company's proprietary Helinx technology and is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells. INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600